|
시장보고서
상품코드
2024441
MRSA 치료제 시장 규모 : MRSA 유형, 약제 클래스별, 적응증, 투여 경로, 유통 채널 및 지역별(2026-2034년)MRSA Drugs Market Size by MRSA Type (Hospital-Acquired, Community-Acquired), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2026-2034 |
||||||
세계의 MRSA 치료제 시장 규모는 2025년에 40억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 52억 달러에 달하며, 2026-2034년에 CAGR 2.89%로 성장할 것으로 예측하고 있습니다. 항생제 내성균 발생률 증가, 장기 입원에 따른 의료기관내 다제내성균에 대한 지속적인 노출, 임상시험 증가 등이 시장을 촉진하는 주요 요인으로 작용하고 있습니다.
메티실린 내성 황색포도상구균(MRSA)은 항생제 내성을 가진 황색포도상구균 균주에 의해 발생하는 감염으로, 일반적으로 외과수술을 받는 환자, 정맥 카테터를 삽입한 환자 또는 환자 간 피부와 피부가 접촉하는 경우에 발생합니다. MRSA 치료제는 메티실린 내성 황색포도상구균 감염에 대한 항균제로서 병원균을 사멸시키거나 증식을 억제하는 데 사용됩니다. 이들은 병원균의 작용을 억제하는 동시에 환자의 세포 합성 및 면역 기능을 강화합니다. 가장 일반적인 MRSA 치료제에는 트리메토프림 설파메톡사졸, 클린다마이신, 미노사이클린, 리네졸리드, 독시사이클린 등이 있습니다. 이 약들은 일반적으로 경구약으로 사용되며, 보통 7-10일 동안 복용하는 코스입니다. MRSA 감염은 병원내 또는 지역사회에서 발생할 수 있으므로 MRSA 치료는 중증도에 따라 경구약과 정맥주사(IV)를 병용하여 치료할 수 있습니다. 피부 감염, 뼈 감염, 균혈증, 동물의 인수공통전염병 등 다양한 유형의 감염증을 치료할 수 있는 MRSA 치료제가 다수 존재합니다.
MRSA 치료제 시장 동향:
일반인들 사이에서 항생제 내성균의 발생률이 증가하고 있는 것이 시장 성장을 촉진하는 중요한 요인으로 작용하고 있습니다. 이는 전 세계에서 병원내 감염(HAI) 사례가 증가하고 있기 때문인 것으로 보입니다. 또한 장기 입원으로 인한 의료기관내 다제내성균에 대한 지속적인 노출이 2차 병원내 감염을 유발하고 있으며, 이는 시장 확대를 견인하고 있습니다. 또한 MRSA 감염에 취약한 고령 인구의 증가도 시장을 촉진하는 요인으로 작용하고 있습니다. 또한 다양한 형태의 세균 감염에 대한 인식이 높아지면서 MRSA 치료제의 채택이 확대되고 있습니다. 이에 따라 수많은 제품 혁신, 임상 시험의 증가 및 새로운 약물의 도입으로 인해 시장에서 유망한 성장 기회를 창출하고 있습니다. 그러나 신규 MRSA 치료제 개발에 따른 고비용은 시장의 성장을 저해하는 주요 요인으로 작용하고 있습니다. 한편, 다양한 진단 툴의 지속적인 기술 개발과 더불어 항생제 내성 균주 스크리닝을 위한 임상 시험 프로그램의 증가는 시장에 밝은 전망을 가져다주고 있습니다. 또한 주요 기업의 광범위한 연구개발(R&D) 활동도 시장을 더욱 견인하고 있습니다. 기타 시장 확대에 기여하는 요인으로는 현재 시판 중인 제품에 대한 제네릭 의약품의 등장, 온라인 및 오프라인의 조직화된 플랫폼을 통한 항생제 접근성, 급속한 도시화, 그리고 의료비 증가 등을 들 수 있습니다.
이 보고서에서 답변하는 주요 질문:
- 지금까지의 세계 MRSA 치료제 시장 동향은 어떠했으며, 향후 수년간 어떻게 변화하는가?
- 세계의 MRSA 치료제 시장 촉진요인, 제약 요인 및 기회는 무엇인가?
- 주요 지역 시장은 어디인가?
- 가장 매력적인 MRSA 치료제 시장을 형성하고 있는 국가는 어디인가?
- MRSA 유형별로 보면 시장 분석은 어떻게 이루어지는가?
- 약제 클래스별 시장 현황은?
- 질병 적응증에 따른 시장 분석은 어떻게 이루어지는가?
- 투여경로별 시장 현황은?
- 유통 채널별 시장 현황은?
- 세계의 MRSA 치료제 시장의 경쟁 구조는 어떠한가?
- 세계의 MRSA 치료제 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 MRSA 치료제 시장
제6장 시장 내역 : MRSA 유형별
제7장 시장 내역 : 약제 클래스별
제8장 시장 내역 : 질환 적응증별
제9장 시장 내역 : 투여 경로별
제10장 시장 내역 : 유통 채널별
제11장 시장 내역 : 지역별
제12장 촉진요인·억제요인·기회
제13장 밸류체인 분석
제14장 Porters Five Forces 분석
제15장 가격 분석
제16장 경쟁 구도
KSA 26.05.14The global MRSA drugs market size reached USD 4.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 2.89% during 2026-2034. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.
Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.
MRSA Drugs Market Trends:
The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global MRSA drugs market, along with forecasts at the global, regional, and country level from 2026-2034. Our report has categorized the market based on MRSA type, drug class, disease indication, route of administration, and distribution channel.
MRSA Type Insights
- Hospital-Acquired (HA-MRSA)
- Community-Acquired (CA-MRSA)
Drug Class Insights
- Lipopeptides
- Oxazolidinones
- Cephalosporin
- Tetracycline
- Folate Antagonist
- Others
Disease Indication Insights
- Skin Infections
- Bone and Joint Infections
- Bacteremia
- Animal Infections
Route of Administration Insights
- Oral Administration
- Parenteral Administration
Distribution Channel Insights
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.
Key Questions Answered in This Report:
- How has the global MRSA drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global MRSA drugs market?
- What are the key regional markets?
- Which countries represent the most attractive MRSA drugs markets?
- What is the breakup of the market based on the MRSA type?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the disease indication?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What is the competitive structure of the global MRSA drugs market?
- Who are the key players/companies in the global MRSA drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global MRSA Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by MRSA Type
- 6.1 Hospital-Acquired (HA-MRSA)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Community-Acquired (CA-MRSA)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Lipopeptides
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Oxazolidinones
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cephalosporin
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Tetracycline
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Folate Antagonist
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Disease Indication
- 8.1 Skin Infections
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Bone and Joint Infections
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Bacteremia
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Animal Infections
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Route of Administration
- 9.1 Oral Administration
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Parenteral Administration
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
10 Market Breakup by Distribution Channel
- 10.1 Hospital Pharmacies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Online Pharmacies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.1.1 United States
- 11.2 Asia-Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.2.1 China
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.3.1 Germany
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.4.1 Brazil
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
12 Drivers, Restraints, and Opportunities
- 12.1 Overview
- 12.2 Drivers
- 12.3 Restraints
- 12.4 Opportunities
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 AbbVie Inc.
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 Basilea Pharmaceutica Ltd
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.3 Crystal Genomics Inc.
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.4 Cumberland Pharmaceuticals Inc
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.5 Melinta Therapeutics Inc
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 Financials
- 16.3.6 Paratek Pharmaceuticals, Inc.
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.6.4 SWOT Analysis
- 16.3.7 Pfizer Inc
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.7.4 SWOT Analysis
- 16.3.1 AbbVie Inc.
